Home

kolónia Olvasni transzparens median overall survival Szövetségi Átlátszó szlogen

Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma:  retrospective real-life data | World Journal of Surgical Oncology | Full  Text
Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data | World Journal of Surgical Oncology | Full Text

Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)

Novel models for prediction of benefit and toxicity with FOLFIRINOX  treatment of pancreatic cancer using clinically available parameters | PLOS  ONE
Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters | PLOS ONE

Progression free survival rate at 9 and 18 weeks predict overall survival  in patients with malignant pleural mesothelioma: An individual patient  pooled analysis of 10 European Organisation for Research and Treatment of
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of

Cureus | Impact of CyberKnife Radiosurgery on Median Overall Survival of  Various Parameters in Patients with 1-12 Brain Metastases
Cureus | Impact of CyberKnife Radiosurgery on Median Overall Survival of Various Parameters in Patients with 1-12 Brain Metastases

Survival (time to event) data: median survival times | The BMJ
Survival (time to event) data: median survival times | The BMJ

Acute lymphoblastic leukemia: A population‐based study of outcome in the  United States based on the surveillance, epidemiology, and end results  (SEER) database, 1980–2017 - Sasaki - 2021 - American Journal of Hematology  - Wiley Online Library
Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017 - Sasaki - 2021 - American Journal of Hematology - Wiley Online Library

Median overall survival (mOS) and median progression-free survival... |  Download Scientific Diagram
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram

Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC

View Image
View Image

Evidence for improved survival with bevacizumab treatment in recurrent  high-grade gliomas: a retrospective study with (“pseudo-randomized”)  treatment allocation by the health insurance provider | SpringerLink
Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with (“pseudo-randomized”) treatment allocation by the health insurance provider | SpringerLink

IMFINZI® (durvalumab) Efficacy & Clinical Trials for ES-SCLC
IMFINZI® (durvalumab) Efficacy & Clinical Trials for ES-SCLC

Cancers | Free Full-Text | Role of Postoperative Complications in Overall  Survival after Radical Resection for Gastric Cancer: A Retrospective  Single-Center Analysis of 1107 Patients
Cancers | Free Full-Text | Role of Postoperative Complications in Overall Survival after Radical Resection for Gastric Cancer: A Retrospective Single-Center Analysis of 1107 Patients

PADCEV® (enfortumab vedotin-ejfv) Efficacy in Patients with la/mUC
PADCEV® (enfortumab vedotin-ejfv) Efficacy in Patients with la/mUC

Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer  | NEJM
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM

VYXEOS® Efficacy - Phase 3 Trial Data vs 7+3 | VYXEOS® (daunorubicin and  cytarabine)
VYXEOS® Efficacy - Phase 3 Trial Data vs 7+3 | VYXEOS® (daunorubicin and cytarabine)

NEJM on Twitter: "Nivolumab increases median overall survival by 5.4 months  in adv renal cell cancer. #ECC2015 http://t.co/9DSZcnbnAs  http://t.co/22qcFuEfzN" / Twitter
NEJM on Twitter: "Nivolumab increases median overall survival by 5.4 months in adv renal cell cancer. #ECC2015 http://t.co/9DSZcnbnAs http://t.co/22qcFuEfzN" / Twitter

View Image
View Image

Efficacy Results | ONIVYDE® (irinotecan liposome injection) | HCP | Onivyde
Efficacy Results | ONIVYDE® (irinotecan liposome injection) | HCP | Onivyde

Download Revlimid Dex Median Overall Survival In Non-transplant - Overall  Survival PNG Image with No Background - PNGkey.com
Download Revlimid Dex Median Overall Survival In Non-transplant - Overall Survival PNG Image with No Background - PNGkey.com

Median Survival Time - an overview | ScienceDirect Topics
Median Survival Time - an overview | ScienceDirect Topics

Cancers | Free Full-Text | Identification of Predictive Factors for Overall  Survival and Response during Hypomethylating Treatment in Very Elderly  (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life  Experience
Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience

Cureus | Impact of CyberKnife Radiosurgery on Median Overall Survival of  Various Parameters in Patients with 1-12 Brain Metastases
Cureus | Impact of CyberKnife Radiosurgery on Median Overall Survival of Various Parameters in Patients with 1-12 Brain Metastases

Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for  Inoperable, Locally Advanced Pancreatic Cancer with
Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with

View Image
View Image

Overall survival curve. Median overall survival time was 8.2 months.... |  Download Scientific Diagram
Overall survival curve. Median overall survival time was 8.2 months.... | Download Scientific Diagram

Disparities in Care and Outcomes
Disparities in Care and Outcomes